Ermium Therapeutics is a biotech company developing innovative therapies for auto-immune diseases, based on a breakthrough discovery showing that CXCR4 is a master regulator of inflammation.
Total raised: $13.484165M
Founded date: 2019
Investors 2
Date | Name | Website |
- | Idinvest P... | idinvest.c... |
- | Kurma Part... | kurmapartn... |
Funding Rounds 2
Date | Series | Amount | Investors | Deal News |
04.07.2022 | - | $6.552275M | - | fh-partner... |
11.09.2019 | Series A | $6.93189M | - | biospace.c... |
Mentions in press and media 5
Date | Title | Description | Source |
10.11.2023 | Which Parisian Biotech Startups are Pioneering Industry Inno... | Paris, the global hub for art, fashion, gastronomy, and culture is now extensively recognized for it... | eustartup.... |
19.09.2023 | Which Biotech Startups are Transforming Ile-de-France’s Indu... | Ile-de-France, a densely populated region encompassing the French capital, Paris, is also emerging a... | eustartup.... |
04.07.2022 | Ermium Therapeutics Raises Further €6M in Funding; Brings To... | Ermium Therapeutics, a Paris, France-based biotech company, raised €6.3M in funding, bringing total ... | finsmes.co... |
30.06.2022 | Ermium Therapeutics extends its initial €6.3 M funding to ... | Ermium Therapeutics, a Paris-based biotech company developing innovative health products for auto-im... | fh-partner... |
- | Ermium Therapeutics Strengthen Its Leadership Team With the ... | PARIS--(BUSINESS WIRE)--Mar 9, 2021-- Ermium Therapeutics SAS, a research-stage biotechnology compa... | oaoa.com/n... |